Sicor, Inc.

FDA gives ANDA approval for norepinephrine bitartrate injection

Published in Drug Week, March 28th, 2003

Sicor, Inc., (SCRI) announced that its wholly owned subsidiary, Gensia Sicor Pharmaceuticals, Inc., has received approval of an abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for norepinephrine bitartrate injection.

Norepinephrine bitartrate is used to restore blood pressure and control acute hypotensive states and as an adjunct in the treatment of cardiac arrest and profound hypotension.

The product is packaged in an ampule.

Gensia Sicor's version of norepinephrine injection will be available in a user-friendly 5 mL flip-top vial.

This article was prepared by Drug Week...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-03-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry